Stay updated on Pembrolizumab & Lanreotide for GI NETs Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.

Latest updates to the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page
- Check2 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed. No changes to core content, pricing, stock, or scheduling.SummaryDifference0.2%
- Check9 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.2%
- Check16 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as the introduction of specific medical terms related to gastro-enteropancreatic neuroendocrine tumors and associated treatments. However, many previously listed terms and resources have been removed.SummaryDifference4%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated to version 2.16.12, replacing the previous version 2.16.11.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check46 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.9%
Stay in the know with updates to Pembrolizumab & Lanreotide for GI NETs Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.